Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/106114
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fonteles, Analu A. | - |
dc.contributor.author | Neves, Julliana C. S. | - |
dc.contributor.author | Menezes, Ana Paula F. | - |
dc.contributor.author | Pereira, Juliana F. | - |
dc.contributor.author | Silva, Ana Thais A. | - |
dc.contributor.author | Cunha, Rodrigo A. | - |
dc.contributor.author | Andrade, Geanne M. | - |
dc.date.accessioned | 2023-03-21T10:29:13Z | - |
dc.date.available | 2023-03-21T10:29:13Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1662-5099 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/106114 | - |
dc.description.abstract | Dopamine replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA) is the only temporary therapy for Parkinson's disease (PD), but it triggers dyskinesia over time. Since dyskinesia is associated with increased neuronal firing that bolsters purinergic signaling, we now tested whether the selective and blood-brain barrier-permeable P2X7 receptor antagonist Brilliant Blue-G (BBG, 22.5-45 mg/kg ip) attenuated behavioral, neurochemical and biochemical alterations in rats turned hemiparkinsonian upon unilateral striatal injection of 6-hydroxydopamine (6-OHDA) and treated daily with L-DOPA (30 mg/kg by gavage) for 22 days. The blockade of P2X7 receptors decreased L-DOPA-induced dyskinesia and motor incoordination in hemiparkinsonian rats. In parallel, BBG treatment rebalanced the altered dopamine D1 and D2 receptor density and signaling as well as some neuroinflammation-associated parameters in the striatum and substantia nigra. These findings herald a hitherto unrecognized role for purinergic signaling in the etiopathology of dyskinesia and prompt P2X7 receptor antagonists as novel candidate anti-dyskinesia drugs. | pt |
dc.description.sponsorship | National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq) | pt |
dc.language.iso | eng | pt |
dc.publisher | Frontiers Media S.A. | pt |
dc.relation | La Caixa Foundation (LCF/PR/HP17/52190001) | pt |
dc.relation | CENTRO-01-0145- FEDER-000008:BrainHealth 2020 | pt |
dc.relation | FCT; POCI-01-0145-FEDER-03127 | pt |
dc.relation | H2020-WIDESPREAD-2018-01 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | Parkinson’s disease | pt |
dc.subject | dyskinesia | pt |
dc.subject | P2X7 receptor | pt |
dc.subject | neuroinflammation | pt |
dc.subject | dopamine D1 receptor | pt |
dc.subject | striatum | pt |
dc.subject | microglia | pt |
dc.subject | astrocyte | pt |
dc.title | ATP Signaling Controlling Dyskinesia Through P2X7 Receptors | pt |
dc.type | article | - |
degois.publication.firstPage | 111 | pt |
degois.publication.title | Frontiers in Molecular Neuroscience | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3389/fnmol.2020.00111 | pt |
degois.publication.volume | 13 | pt |
dc.date.embargo | 2020-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0003-2550-6422 | - |
Appears in Collections: | I&D CNC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ATP Signaling Controlling Dyskinesia Through P2X7 Receptors.pdf | 3.56 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
12
checked on Oct 7, 2024
WEB OF SCIENCETM
Citations
11
checked on Oct 2, 2024
Page view(s)
90
checked on Oct 9, 2024
Download(s)
49
checked on Oct 9, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License